[Risk of superinfection related to antibiotic use. Are all antibiotics the same?]

Area of Science:

• Infectious Diseases
• Pharmacology
• Hospital Epidemiology

Background:

• Hospital-acquired infections (HAIs) pose significant risks to patient outcomes.
• The use of broad-spectrum antibiotics can disrupt the normal microbiota, increasing susceptibility to superinfections.
• Understanding the relationship between specific antibiotics and superinfection risk is crucial for optimizing treatment strategies.

Purpose of the Study:

• To systematically review and analyze the impact of different antibiotic classes on the incidence of bacterial and fungal superinfections in patients with HAIs.
• To identify specific antibiotics associated with a higher or lower risk of developing superinfections.

Main Methods:

• A systematic literature review was conducted using the PubMed (Medline) database, covering publications from January 1990 to December 2003.
• Studies included had at least 25 patients per treatment arm, evaluated the clinical efficacy of third-generation cephalosporins, fluoroquinolones, piperacillin-tazobactam, or carbapenems, and reported superinfection rates.

Main Results:

• Candida spp. were the most common superinfecting organisms (42.3%), followed by Enterococcus spp. (18.8%) and enterobacteria (13.8%).
• Ciprofloxacin was associated with the highest superinfection rate (38.1%), followed by cefotaxime (23.3%).
• Piperacillin-tazobactam demonstrated the lowest superinfection percentage (5.4%).

Conclusions:

• Antibiotic selection significantly influences the risk of superinfections in the context of HAIs.
• Piperacillin-tazobactam appears to be associated with a lower risk of superinfection compared to other evaluated antibiotics, including fluoroquinolones and third-generation cephalosporins.
• Further research and careful antibiotic stewardship are warranted to minimize superinfection rates in hospitalized patients.